Anixa Biosciences (NASDAQ:ANIX) vs. I-Mab (NASDAQ:IMAB) Financial Survey

I-Mab (NASDAQ:IMAB) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares I-Mab and Anixa Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Anixa Biosciences	N/A	-54.79%	-50.37%

Risk & Volatility

I-Mab has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for I-Mab and Anixa Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0	0	4	0	3.00
Anixa Biosciences	0	0	1	1	3.50

I-Mab currently has a consensus price target of $8.00, indicating a potential upside of 647.66%. Anixa Biosciences has a consensus price target of $7.00, indicating a potential upside of 100.00%. Given I-Mab’s higher possible upside, equities research analysts plainly believe I-Mab is more favorable than Anixa Biosciences.

Valuation & Earnings

This table compares I-Mab and Anixa Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.59 million	24.29	-$206.44 million	N/A	N/A
Anixa Biosciences	$210,000.00	536.32	-$9.81 million	($0.39)	-8.97

Anixa Biosciences has lower revenue, but higher earnings than I-Mab.

Institutional & Insider Ownership

38.4% of I-Mab shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 22.6% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

I-Mab beats Anixa Biosciences on 7 of the 12 factors compared between the two stocks.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.